Carmen Pinto, M.D.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$89,238.21	27.1%	84	2025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$72,139.42	21.9%	83	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$49,431.40	15.0%	64	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$48,281.63	14.7%	65	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$35,804.63	10.9%	33	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$22,830.36	6.9%	27	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$11,669.74	3.5%	11	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$19.93	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$248,357.50	89
Honoraria	$33,850.00	12
Travel and Lodging	$21,740.15	133
Consulting Fee	$19,090.00	8
Food and Beverage	$6,377.67	126

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$72,139.42	83	2025
Source payment records 2025-01-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.93 · Open Payments source 2025-01-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,940.00 · Open Payments source 2025-01-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $203.00 · Open Payments source 2025-01-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,940.00 · Open Payments source 2025-01-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $171.19 · Open Payments source 2025-01-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $175.00 · Open Payments source 2025-01-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $38.51 · Open Payments source 2025-01-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,680.00 · Open Payments source 2025-01-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $63.00 · Open Payments source 2025-01-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.78 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,940.00 · Open Payments source 2025-03-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.50 · Open Payments source 2025-03-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,680.00 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,680.00 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.00 · Open Payments source 2025-06-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.71 · Open Payments source 2025-06-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.32 · Open Payments source 2025-06-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-07-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-07-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $119.70 · Open Payments source 2025-07-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.69 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-08-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $90.59 · Open Payments source 2025-08-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.06 · Open Payments source 2025-08-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,400.00 · Open Payments source 2025-09-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.41 · Open Payments source 2025-09-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $348.60 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.41 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-09-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.79 · Open Payments source 2025-09-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.91 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-09-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-09-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $156.80 · Open Payments source 2025-09-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.00 · Open Payments source 2025-09-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $70.00 · Open Payments source 2025-09-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $70.00 · Open Payments source 2025-09-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $91.67 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $450.97 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.22 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.69 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-10-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.96 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.53 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.94 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $38.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $133.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.77 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $119.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $210.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $63.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.00 · Open Payments source 2025-11-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.29 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $123.97 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $133.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $154.00 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $121.86 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.08 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $196.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.00 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.00 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $133.00 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$49,431.40	64	2025
Source payment records 2025-01-24 · Janssen Pharmaceuticals, Inc · $522.35 · Open Payments source 2025-01-27 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-02-06 · Janssen Pharmaceuticals, Inc · $34.09 · Open Payments source 2025-02-06 · Janssen Pharmaceuticals, Inc · $156.52 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $238.30 · Open Payments source 2025-02-11 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-02-11 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-02-11 · Janssen Pharmaceuticals, Inc · $1,575.00 · Open Payments source 2025-02-26 · Janssen Pharmaceuticals, Inc · $143.36 · Open Payments source 2025-02-27 · Janssen Pharmaceuticals, Inc · $220.50 · Open Payments source 2025-03-04 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-03-05 · Janssen Pharmaceuticals, Inc · $308.00 · Open Payments source 2025-03-08 · Janssen Pharmaceuticals, Inc · $56.00 · Open Payments source 2025-03-08 · Janssen Pharmaceuticals, Inc · $40.00 · Open Payments source 2025-03-08 · Janssen Pharmaceuticals, Inc · $104.17 · Open Payments source 2025-03-08 · Janssen Pharmaceuticals, Inc · $33.00 · Open Payments source 2025-03-13 · Janssen Pharmaceuticals, Inc · $17.22 · Open Payments source 2025-03-18 · Janssen Pharmaceuticals, Inc · $196.00 · Open Payments source 2025-03-19 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-05-02 · Janssen Pharmaceuticals, Inc · $18.80 · Open Payments source 2025-05-06 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-05-07 · Janssen Pharmaceuticals, Inc · $259.00 · Open Payments source 2025-05-20 · Janssen Pharmaceuticals, Inc · $17.06 · Open Payments source 2025-05-23 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-05-27 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-05-28 · Janssen Pharmaceuticals, Inc · $37.49 · Open Payments source 2025-05-28 · Janssen Pharmaceuticals, Inc · $23.67 · Open Payments source 2025-05-28 · Janssen Pharmaceuticals, Inc · $179.20 · Open Payments source 2025-05-28 · Janssen Pharmaceuticals, Inc · $112.48 · Open Payments source 2025-05-28 · Janssen Pharmaceuticals, Inc · $10.12 · Open Payments source 2025-06-03 · Janssen Pharmaceuticals, Inc · $236.28 · Open Payments source 2025-06-03 · Janssen Pharmaceuticals, Inc · $277.90 · Open Payments source 2025-06-07 · Janssen Pharmaceuticals, Inc · $1,575.00 · Open Payments source 2025-06-07 · Janssen Pharmaceuticals, Inc · $277.90 · Open Payments source 2025-06-13 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-06-19 · Janssen Pharmaceuticals, Inc · $444.23 · Open Payments source 2025-06-20 · Janssen Pharmaceuticals, Inc · $147.11 · Open Payments source 2025-06-21 · Janssen Pharmaceuticals, Inc · $20.84 · Open Payments source 2025-06-25 · Janssen Pharmaceuticals, Inc · $189.00 · Open Payments source 2025-06-25 · Janssen Pharmaceuticals, Inc · $140.00 · Open Payments source 2025-06-27 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-06-27 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-07-01 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-07-12 · Janssen Pharmaceuticals, Inc · $450.00 · Open Payments source 2025-07-22 · Janssen Pharmaceuticals, Inc · $129.37 · Open Payments source 2025-07-23 · Janssen Pharmaceuticals, Inc · $114.88 · Open Payments source 2025-07-23 · Janssen Pharmaceuticals, Inc · $17.55 · Open Payments source 2025-07-24 · Janssen Pharmaceuticals, Inc · $588.73 · Open Payments source 2025-07-25 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-07-25 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-07-29 · Janssen Pharmaceuticals, Inc · $1,575.00 · Open Payments source 2025-07-30 · Janssen Pharmaceuticals, Inc · $44.99 · Open Payments source 2025-08-05 · Janssen Pharmaceuticals, Inc · $98.00 · Open Payments source 2025-08-06 · Janssen Pharmaceuticals, Inc · $2,700.00 · Open Payments source 2025-08-20 · Janssen Pharmaceuticals, Inc · $22.56 · Open Payments source 2025-08-22 · Janssen Pharmaceuticals, Inc · $23.27 · Open Payments source 2025-08-22 · Janssen Pharmaceuticals, Inc · $137.26 · Open Payments source 2025-08-22 · Janssen Pharmaceuticals, Inc · $46.00 · Open Payments source 2025-08-22 · Janssen Pharmaceuticals, Inc · $56.00 · Open Payments source 2025-08-26 · Janssen Pharmaceuticals, Inc · $2,700.00 · Open Payments source 2025-09-15 · Janssen Pharmaceuticals, Inc · $900.00 · Open Payments source 2025-10-21 · Janssen Pharmaceuticals, Inc · $19.38 · Open Payments source 2025-10-21 · Janssen Pharmaceuticals, Inc · $0.82 · Open Payments source 2025-12-17 · Janssen Pharmaceuticals, Inc · $675.00 · Open Payments source
INVEGA TRINZA Normalized: invega trinza	Drug	Janssen Pharmaceuticals, Inc	$48,343.09	45	2025
Source payment records 2025-01-24 · Janssen Pharmaceuticals, Inc · $522.35 · Open Payments source 2025-01-27 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $238.30 · Open Payments source 2025-02-11 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-02-11 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-02-11 · Janssen Pharmaceuticals, Inc · $1,575.00 · Open Payments source 2025-02-27 · Janssen Pharmaceuticals, Inc · $220.50 · Open Payments source 2025-03-04 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-03-05 · Janssen Pharmaceuticals, Inc · $308.00 · Open Payments source 2025-03-08 · Janssen Pharmaceuticals, Inc · $56.00 · Open Payments source 2025-03-08 · Janssen Pharmaceuticals, Inc · $40.00 · Open Payments source 2025-03-08 · Janssen Pharmaceuticals, Inc · $104.17 · Open Payments source 2025-03-08 · Janssen Pharmaceuticals, Inc · $33.00 · Open Payments source 2025-03-18 · Janssen Pharmaceuticals, Inc · $196.00 · Open Payments source 2025-03-19 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-05-06 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-05-07 · Janssen Pharmaceuticals, Inc · $259.00 · Open Payments source 2025-05-23 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-05-27 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-05-28 · Janssen Pharmaceuticals, Inc · $179.20 · Open Payments source 2025-06-03 · Janssen Pharmaceuticals, Inc · $236.28 · Open Payments source 2025-06-03 · Janssen Pharmaceuticals, Inc · $277.90 · Open Payments source 2025-06-07 · Janssen Pharmaceuticals, Inc · $1,575.00 · Open Payments source 2025-06-07 · Janssen Pharmaceuticals, Inc · $277.90 · Open Payments source 2025-06-13 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-06-19 · Janssen Pharmaceuticals, Inc · $444.23 · Open Payments source 2025-06-25 · Janssen Pharmaceuticals, Inc · $189.00 · Open Payments source 2025-06-25 · Janssen Pharmaceuticals, Inc · $140.00 · Open Payments source 2025-06-27 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-06-27 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-07-01 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-07-12 · Janssen Pharmaceuticals, Inc · $450.00 · Open Payments source 2025-07-24 · Janssen Pharmaceuticals, Inc · $588.73 · Open Payments source 2025-07-25 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-07-25 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-07-29 · Janssen Pharmaceuticals, Inc · $1,575.00 · Open Payments source 2025-08-05 · Janssen Pharmaceuticals, Inc · $98.00 · Open Payments source 2025-08-06 · Janssen Pharmaceuticals, Inc · $2,700.00 · Open Payments source 2025-08-22 · Janssen Pharmaceuticals, Inc · $23.27 · Open Payments source 2025-08-22 · Janssen Pharmaceuticals, Inc · $137.26 · Open Payments source 2025-08-22 · Janssen Pharmaceuticals, Inc · $46.00 · Open Payments source 2025-08-22 · Janssen Pharmaceuticals, Inc · $56.00 · Open Payments source 2025-08-26 · Janssen Pharmaceuticals, Inc · $2,700.00 · Open Payments source 2025-09-15 · Janssen Pharmaceuticals, Inc · $900.00 · Open Payments source 2025-12-17 · Janssen Pharmaceuticals, Inc · $675.00 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$45,586.65	53	2025
Source payment records 2025-02-11 · Otsuka America Pharmaceutical, Inc. · $79.34 · Open Payments source 2025-02-12 · Otsuka America Pharmaceutical, Inc. · $81.08 · Open Payments source 2025-02-19 · Otsuka America Pharmaceutical, Inc. · $2,548.00 · Open Payments source 2025-02-27 · Otsuka America Pharmaceutical, Inc. · $90.42 · Open Payments source 2025-02-27 · Otsuka America Pharmaceutical, Inc. · $121.82 · Open Payments source 2025-02-27 · Otsuka America Pharmaceutical, Inc. · $90.42 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $3,136.00 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $271.25 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $271.25 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-03-15 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-03-15 · Otsuka America Pharmaceutical, Inc. · $300.00 · Open Payments source 2025-04-10 · Otsuka America Pharmaceutical, Inc. · $123.29 · Open Payments source 2025-04-10 · Otsuka America Pharmaceutical, Inc. · $27.90 · Open Payments source 2025-04-10 · Otsuka America Pharmaceutical, Inc. · $17.22 · Open Payments source 2025-04-11 · Otsuka America Pharmaceutical, Inc. · $307.50 · Open Payments source 2025-04-16 · Otsuka America Pharmaceutical, Inc. · $8,526.00 · Open Payments source 2025-04-24 · Otsuka America Pharmaceutical, Inc. · $121.80 · Open Payments source 2025-04-24 · Otsuka America Pharmaceutical, Inc. · $22.74 · Open Payments source 2025-04-24 · Otsuka America Pharmaceutical, Inc. · $196.00 · Open Payments source 2025-04-24 · Otsuka America Pharmaceutical, Inc. · $108.50 · Open Payments source 2025-05-09 · Otsuka America Pharmaceutical, Inc. · $351.00 · Open Payments source 2025-05-15 · Otsuka America Pharmaceutical, Inc. · $16.46 · Open Payments source 2025-05-23 · Otsuka America Pharmaceutical, Inc. · $105.00 · Open Payments source 2025-05-28 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $83.33 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $153.64 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $34.49 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $153.66 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $153.65 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $877.50 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $412.71 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $50.21 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $412.70 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $50.23 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $412.71 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $50.21 · Open Payments source 2025-06-27 · Otsuka America Pharmaceutical, Inc. · $4,312.00 · Open Payments source 2025-06-27 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-07-02 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $66.23 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $13.96 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $40.00 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $8.11 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $21.97 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $6.34 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $14.22 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $26.57 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $56.00 · Open Payments source 2025-08-07 · Otsuka America Pharmaceutical, Inc. · $19.29 · Open Payments source 2025-08-13 · Otsuka America Pharmaceutical, Inc. · $2,548.00 · Open Payments source 2025-08-20 · Otsuka America Pharmaceutical, Inc. · $56.00 · Open Payments source 2025-12-18 · Lundbeck LLC · $19.93 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$45,566.72	52	2025
Source payment records 2025-02-11 · Otsuka America Pharmaceutical, Inc. · $79.34 · Open Payments source 2025-02-12 · Otsuka America Pharmaceutical, Inc. · $81.08 · Open Payments source 2025-02-19 · Otsuka America Pharmaceutical, Inc. · $2,548.00 · Open Payments source 2025-02-27 · Otsuka America Pharmaceutical, Inc. · $90.42 · Open Payments source 2025-02-27 · Otsuka America Pharmaceutical, Inc. · $121.82 · Open Payments source 2025-02-27 · Otsuka America Pharmaceutical, Inc. · $90.42 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $3,136.00 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $271.25 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $271.25 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-03-15 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-03-15 · Otsuka America Pharmaceutical, Inc. · $300.00 · Open Payments source 2025-04-10 · Otsuka America Pharmaceutical, Inc. · $123.29 · Open Payments source 2025-04-10 · Otsuka America Pharmaceutical, Inc. · $27.90 · Open Payments source 2025-04-10 · Otsuka America Pharmaceutical, Inc. · $17.22 · Open Payments source 2025-04-11 · Otsuka America Pharmaceutical, Inc. · $307.50 · Open Payments source 2025-04-16 · Otsuka America Pharmaceutical, Inc. · $8,526.00 · Open Payments source 2025-04-24 · Otsuka America Pharmaceutical, Inc. · $121.80 · Open Payments source 2025-04-24 · Otsuka America Pharmaceutical, Inc. · $22.74 · Open Payments source 2025-04-24 · Otsuka America Pharmaceutical, Inc. · $196.00 · Open Payments source 2025-04-24 · Otsuka America Pharmaceutical, Inc. · $108.50 · Open Payments source 2025-05-09 · Otsuka America Pharmaceutical, Inc. · $351.00 · Open Payments source 2025-05-15 · Otsuka America Pharmaceutical, Inc. · $16.46 · Open Payments source 2025-05-23 · Otsuka America Pharmaceutical, Inc. · $105.00 · Open Payments source 2025-05-28 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $83.33 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $153.64 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $34.49 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $153.66 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $153.65 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $877.50 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $412.71 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $50.21 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $412.70 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $50.23 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $412.71 · Open Payments source 2025-06-26 · Otsuka America Pharmaceutical, Inc. · $50.21 · Open Payments source 2025-06-27 · Otsuka America Pharmaceutical, Inc. · $4,312.00 · Open Payments source 2025-06-27 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-07-02 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $66.23 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $13.96 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $40.00 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $8.11 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $21.97 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $6.34 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $14.22 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $26.57 · Open Payments source 2025-07-09 · Otsuka America Pharmaceutical, Inc. · $56.00 · Open Payments source 2025-08-07 · Otsuka America Pharmaceutical, Inc. · $19.29 · Open Payments source 2025-08-13 · Otsuka America Pharmaceutical, Inc. · $2,548.00 · Open Payments source 2025-08-20 · Otsuka America Pharmaceutical, Inc. · $56.00 · Open Payments source
REXULTI Normalized: rexulti	Drug	Otsuka America Pharmaceutical, Inc.	$43,671.49	32	2025
Source payment records 2025-02-10 · Otsuka America Pharmaceutical, Inc. · $30.02 · Open Payments source 2025-02-12 · Otsuka America Pharmaceutical, Inc. · $81.07 · Open Payments source 2025-02-14 · Otsuka America Pharmaceutical, Inc. · $4,312.00 · Open Payments source 2025-02-24 · Otsuka America Pharmaceutical, Inc. · $19.52 · Open Payments source 2025-02-25 · Otsuka America Pharmaceutical, Inc. · $30.28 · Open Payments source 2025-03-03 · Otsuka America Pharmaceutical, Inc. · $116.75 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $168.00 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $15.92 · Open Payments source 2025-03-07 · Otsuka America Pharmaceutical, Inc. · $15.32 · Open Payments source 2025-03-08 · Otsuka America Pharmaceutical, Inc. · $2,548.00 · Open Payments source 2025-03-08 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-03-08 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-03-12 · Otsuka America Pharmaceutical, Inc. · $210.00 · Open Payments source 2025-03-12 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-03-12 · Otsuka America Pharmaceutical, Inc. · $126.00 · Open Payments source 2025-03-20 · Otsuka America Pharmaceutical, Inc. · $224.00 · Open Payments source 2025-04-24 · Otsuka America Pharmaceutical, Inc. · $120.58 · Open Payments source 2025-05-02 · Otsuka America Pharmaceutical, Inc. · $105.00 · Open Payments source 2025-05-02 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-05-07 · Otsuka America Pharmaceutical, Inc. · $119.00 · Open Payments source 2025-05-16 · Otsuka America Pharmaceutical, Inc. · $2,548.00 · Open Payments source 2025-05-21 · Otsuka America Pharmaceutical, Inc. · $11.19 · Open Payments source 2025-05-28 · Otsuka America Pharmaceutical, Inc. · $2,548.00 · Open Payments source 2025-06-06 · Otsuka America Pharmaceutical, Inc. · $77.00 · Open Payments source 2025-06-12 · Otsuka America Pharmaceutical, Inc. · $68.34 · Open Payments source 2025-06-18 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-07-16 · Otsuka America Pharmaceutical, Inc. · $119.70 · Open Payments source 2025-07-23 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-08-28 · Otsuka America Pharmaceutical, Inc. · $20.80 · Open Payments source 2025-09-04 · Otsuka America Pharmaceutical, Inc. · $3,724.00 · Open Payments source 2025-09-10 · Otsuka America Pharmaceutical, Inc. · $245.00 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$35,804.63	33	2025
Source payment records 2025-02-12 · Axsome Therapeutics, Inc. · $2,500.00 · Open Payments source 2025-02-12 · Axsome Therapeutics, Inc. · $20.24 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $48.79 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $125.13 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $45.30 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $60.36 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $26.77 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $78.04 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $29.45 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $32.93 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $234.83 · Open Payments source 2025-03-19 · Axsome Therapeutics, Inc. · $3,575.00 · Open Payments source 2025-03-19 · Axsome Therapeutics, Inc. · $118.75 · Open Payments source 2025-03-19 · Axsome Therapeutics, Inc. · $68.60 · Open Payments source 2025-04-04 · Axsome Therapeutics, Inc. · $8,250.00 · Open Payments source 2025-04-08 · Axsome Therapeutics, Inc. · $196.00 · Open Payments source 2025-05-12 · Axsome Therapeutics, Inc. · $2,750.00 · Open Payments source 2025-05-12 · Axsome Therapeutics, Inc. · $74.20 · Open Payments source 2025-05-14 · Axsome Therapeutics, Inc. · $2,475.00 · Open Payments source 2025-05-14 · Axsome Therapeutics, Inc. · $119.70 · Open Payments source 2025-05-14 · Axsome Therapeutics, Inc. · $65.10 · Open Payments source 2025-05-23 · Axsome Therapeutics, Inc. · $1,650.00 · Open Payments source 2025-06-19 · Axsome Therapeutics, Inc. · $1,100.00 · Open Payments source 2025-07-01 · Axsome Therapeutics, Inc. · $1,650.00 · Open Payments source 2025-07-15 · Axsome Therapeutics, Inc. · $1,100.00 · Open Payments source 2025-08-21 · Axsome Therapeutics, Inc. · $3,575.00 · Open Payments source 2025-08-21 · Axsome Therapeutics, Inc. · $94.50 · Open Payments source 2025-08-21 · Axsome Therapeutics, Inc. · $81.20 · Open Payments source 2025-09-30 · Axsome Therapeutics, Inc. · $2,750.00 · Open Payments source 2025-09-30 · Axsome Therapeutics, Inc. · $249.20 · Open Payments source 2025-10-22 · Axsome Therapeutics, Inc. · $2,475.00 · Open Payments source 2025-10-22 · Axsome Therapeutics, Inc. · $121.14 · Open Payments source 2025-10-22 · Axsome Therapeutics, Inc. · $64.40 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$31,448.16	40	2025
Source payment records 2025-02-13 · Alkermes, Inc. · $14.80 · Open Payments source 2025-02-27 · Alkermes, Inc. · $2,290.00 · Open Payments source 2025-02-27 · Alkermes, Inc. · $84.00 · Open Payments source 2025-03-19 · Alkermes, Inc. · $13.07 · Open Payments source 2025-03-28 · Alkermes, Inc. · $77.00 · Open Payments source 2025-04-04 · Alkermes, Inc. · $2,290.00 · Open Payments source 2025-04-04 · Alkermes, Inc. · $125.00 · Open Payments source 2025-04-04 · Alkermes, Inc. · $23.27 · Open Payments source 2025-04-04 · Alkermes, Inc. · $24.95 · Open Payments source 2025-04-05 · Alkermes, Inc. · $48.66 · Open Payments source 2025-04-05 · Alkermes, Inc. · $75.00 · Open Payments source 2025-04-05 · Alkermes, Inc. · $585.97 · Open Payments source 2025-04-05 · Alkermes, Inc. · $238.26 · Open Payments source 2025-04-05 · Alkermes, Inc. · $2.88 · Open Payments source 2025-04-05 · Alkermes, Inc. · $23.27 · Open Payments source 2025-04-05 · Alkermes, Inc. · $60.00 · Open Payments source 2025-04-05 · Alkermes, Inc. · $23.00 · Open Payments source 2025-04-25 · Alkermes, Inc. · $5,350.00 · Open Payments source 2025-05-13 · Alkermes, Inc. · $28.00 · Open Payments source 2025-05-13 · Alkermes, Inc. · $28.00 · Open Payments source 2025-05-13 · Alkermes, Inc. · $34.00 · Open Payments source 2025-05-19 · Alkermes, Inc. · $202.72 · Open Payments source 2025-05-19 · Alkermes, Inc. · $97.62 · Open Payments source 2025-05-22 · Alkermes, Inc. · $16.02 · Open Payments source 2025-05-30 · Alkermes, Inc. · $3,820.00 · Open Payments source 2025-06-06 · Alkermes, Inc. · $2,290.00 · Open Payments source 2025-06-06 · Alkermes, Inc. · $212.80 · Open Payments source 2025-06-18 · Alkermes, Inc. · $20.84 · Open Payments source 2025-06-30 · Alkermes, Inc. · $26.89 · Open Payments source 2025-07-03 · Alkermes, Inc. · $2,290.00 · Open Payments source 2025-07-03 · Alkermes, Inc. · $140.00 · Open Payments source 2025-07-11 · Alkermes, Inc. · $294.00 · Open Payments source 2025-07-18 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-08-15 · Alkermes, Inc. · $960.00 · Open Payments source 2025-10-30 · Alkermes, Inc. · $21.10 · Open Payments source 2025-11-14 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-11-25 · Alkermes, Inc. · $259.00 · Open Payments source 2025-12-02 · Alkermes, Inc. · $24.04 · Open Payments source 2025-12-12 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-12-15 · Alkermes, Inc. · $154.00 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$20,070.36	23	2025
Source payment records 2025-01-30 · E.R. Squibb & Sons, L.L.C. · $1,610.00 · Open Payments source 2025-03-05 · E.R. Squibb & Sons, L.L.C. · $115.46 · Open Payments source 2025-03-28 · E.R. Squibb & Sons, L.L.C. · $126.00 · Open Payments source 2025-04-07 · E.R. Squibb & Sons, L.L.C. · $3,220.00 · Open Payments source 2025-04-25 · E.R. Squibb & Sons, L.L.C. · $21.55 · Open Payments source 2025-05-20 · E.R. Squibb & Sons, L.L.C. · $112.00 · Open Payments source 2025-05-30 · E.R. Squibb & Sons, L.L.C. · $2,760.00 · Open Payments source 2025-06-10 · E.R. Squibb & Sons, L.L.C. · $126.11 · Open Payments source 2025-06-10 · E.R. Squibb & Sons, L.L.C. · $341.96 · Open Payments source 2025-06-10 · E.R. Squibb & Sons, L.L.C. · $10.41 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $469.00 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $3,956.00 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $1,380.00 · Open Payments source 2025-07-09 · E.R. Squibb & Sons, L.L.C. · $2,300.00 · Open Payments source 2025-07-18 · E.R. Squibb & Sons, L.L.C. · $77.00 · Open Payments source 2025-08-04 · E.R. Squibb & Sons, L.L.C. · $18.77 · Open Payments source 2025-09-23 · E.R. Squibb & Sons, L.L.C. · $1,610.00 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $134.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $1,177.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $326.09 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $51.73 · Open Payments source 2025-11-07 · E.R. Squibb & Sons, L.L.C. · $29.02 · Open Payments source 2025-11-07 · E.R. Squibb & Sons, L.L.C. · $96.28 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$16,833.47	25	2025
Source payment records 2025-01-29 · Alkermes, Inc. · $3.21 · Open Payments source 2025-03-12 · Alkermes, Inc. · $16.42 · Open Payments source 2025-03-20 · Alkermes, Inc. · $2,290.00 · Open Payments source 2025-05-15 · Alkermes, Inc. · $119.16 · Open Payments source 2025-05-30 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-05-30 · Alkermes, Inc. · $59.50 · Open Payments source 2025-06-06 · Alkermes, Inc. · $91.06 · Open Payments source 2025-06-06 · Alkermes, Inc. · $72.14 · Open Payments source 2025-06-06 · Alkermes, Inc. · $32.37 · Open Payments source 2025-06-06 · Alkermes, Inc. · $27.15 · Open Payments source 2025-06-06 · Alkermes, Inc. · $14.67 · Open Payments source 2025-06-06 · Alkermes, Inc. · $12.14 · Open Payments source 2025-06-06 · Alkermes, Inc. · $619.84 · Open Payments source 2025-06-06 · Alkermes, Inc. · $266.96 · Open Payments source 2025-06-06 · Alkermes, Inc. · $179.61 · Open Payments source 2025-06-06 · Alkermes, Inc. · $31.37 · Open Payments source 2025-06-06 · Alkermes, Inc. · $7.11 · Open Payments source 2025-07-08 · Alkermes, Inc. · $56.00 · Open Payments source 2025-07-08 · Alkermes, Inc. · $43.74 · Open Payments source 2025-07-08 · Alkermes, Inc. · $25.09 · Open Payments source 2025-07-08 · Alkermes, Inc. · $193.08 · Open Payments source 2025-07-08 · Alkermes, Inc. · $21.60 · Open Payments source 2025-07-10 · Alkermes, Inc. · $6,500.00 · Open Payments source 2025-07-29 · Alkermes, Inc. · $31.25 · Open Payments source 2025-08-08 · Alkermes, Inc. · $3,060.00 · Open Payments source
ARISTADA INITIO Normalized: aristada initio	Drug	Alkermes, Inc.	$16,833.47	25	2025
Source payment records 2025-01-29 · Alkermes, Inc. · $3.21 · Open Payments source 2025-03-12 · Alkermes, Inc. · $16.42 · Open Payments source 2025-03-20 · Alkermes, Inc. · $2,290.00 · Open Payments source 2025-05-15 · Alkermes, Inc. · $119.16 · Open Payments source 2025-05-30 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-05-30 · Alkermes, Inc. · $59.50 · Open Payments source 2025-06-06 · Alkermes, Inc. · $91.06 · Open Payments source 2025-06-06 · Alkermes, Inc. · $72.14 · Open Payments source 2025-06-06 · Alkermes, Inc. · $32.37 · Open Payments source 2025-06-06 · Alkermes, Inc. · $27.15 · Open Payments source 2025-06-06 · Alkermes, Inc. · $14.67 · Open Payments source 2025-06-06 · Alkermes, Inc. · $12.14 · Open Payments source 2025-06-06 · Alkermes, Inc. · $619.84 · Open Payments source 2025-06-06 · Alkermes, Inc. · $266.96 · Open Payments source 2025-06-06 · Alkermes, Inc. · $179.61 · Open Payments source 2025-06-06 · Alkermes, Inc. · $31.37 · Open Payments source 2025-06-06 · Alkermes, Inc. · $7.11 · Open Payments source 2025-07-08 · Alkermes, Inc. · $56.00 · Open Payments source 2025-07-08 · Alkermes, Inc. · $43.74 · Open Payments source 2025-07-08 · Alkermes, Inc. · $25.09 · Open Payments source 2025-07-08 · Alkermes, Inc. · $193.08 · Open Payments source 2025-07-08 · Alkermes, Inc. · $21.60 · Open Payments source 2025-07-10 · Alkermes, Inc. · $6,500.00 · Open Payments source 2025-07-29 · Alkermes, Inc. · $31.25 · Open Payments source 2025-08-08 · Alkermes, Inc. · $3,060.00 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$11,669.74	11	2025
Source payment records 2025-04-23 · Vanda Pharmaceuticals Inc. · $125.00 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $2,475.00 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $24.14 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $2,145.00 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $159.60 · Open Payments source 2025-08-27 · Vanda Pharmaceuticals Inc. · $2,145.00 · Open Payments source 2025-08-27 · Vanda Pharmaceuticals Inc. · $140.00 · Open Payments source 2025-09-09 · Vanda Pharmaceuticals Inc. · $2,310.00 · Open Payments source 2025-10-08 · Vanda Pharmaceuticals Inc. · $33.00 · Open Payments source 2025-10-08 · Vanda Pharmaceuticals Inc. · $1,980.00 · Open Payments source 2025-10-08 · Vanda Pharmaceuticals Inc. · $133.00 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$329,415.32 · 368 records	Otsuka America Pharmaceutical, Inc.	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, Auvelity, CAPLYTA, COBENFY, FANAPT, INVEGA SUSTENNA, INVEGA TRINZA, LYBALVI, REXULTI	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error

What the public records show

General Payments

Research & Ownership